健康な日本人被験者を対象としたエバセトラピブの研究

基本情報

NCT ID

NCT02226653

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

48

治験依頼者名

Eli Lilly and Company

概要

The purpose of this study is to determine if two different dosing strategies for evacetrapib will have essentially the same effect on the body. The study will also explore the effect of a low fat meal on how the body absorbs evacetrapib. This study will last at least 15 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

対象疾患

介入

依頼者（Sponsor）